Incyte (INCY) Competitors $60.68 -0.58 (-0.95%) Closing price 03/27/2025 04:00 PM EasternExtended Trading$61.33 +0.65 (+1.06%) As of 03/27/2025 04:20 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock INCY vs. ALNY, BIIB, UTHR, BMRN, NBIX, EXEL, EXAS, RGEN, HALO, and MDGLShould you be buying Incyte stock or one of its competitors? The main competitors of Incyte include Alnylam Pharmaceuticals (ALNY), Biogen (BIIB), United Therapeutics (UTHR), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Exelixis (EXEL), Exact Sciences (EXAS), Repligen (RGEN), Halozyme Therapeutics (HALO), and Madrigal Pharmaceuticals (MDGL). These companies are all part of the "biotechnology" industry. Incyte vs. Alnylam Pharmaceuticals Biogen United Therapeutics BioMarin Pharmaceutical Neurocrine Biosciences Exelixis Exact Sciences Repligen Halozyme Therapeutics Madrigal Pharmaceuticals Alnylam Pharmaceuticals (NASDAQ:ALNY) and Incyte (NASDAQ:INCY) are both large-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their profitability, institutional ownership, earnings, risk, dividends, valuation, analyst recommendations, community ranking and media sentiment. Is ALNY or INCY more profitable? Incyte has a net margin of 0.77% compared to Alnylam Pharmaceuticals' net margin of -12.37%. Incyte's return on equity of 0.05% beat Alnylam Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Alnylam Pharmaceuticals-12.37% N/A -6.83% Incyte 0.77%0.05%0.04% Does the media refer more to ALNY or INCY? In the previous week, Alnylam Pharmaceuticals had 34 more articles in the media than Incyte. MarketBeat recorded 61 mentions for Alnylam Pharmaceuticals and 27 mentions for Incyte. Incyte's average media sentiment score of 1.02 beat Alnylam Pharmaceuticals' score of 0.74 indicating that Incyte is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Alnylam Pharmaceuticals 25 Very Positive mention(s) 10 Positive mention(s) 11 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Incyte 17 Very Positive mention(s) 0 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Positive Which has more volatility & risk, ALNY or INCY? Alnylam Pharmaceuticals has a beta of 0.39, suggesting that its share price is 61% less volatile than the S&P 500. Comparatively, Incyte has a beta of 0.76, suggesting that its share price is 24% less volatile than the S&P 500. Does the MarketBeat Community believe in ALNY or INCY? Incyte received 68 more outperform votes than Alnylam Pharmaceuticals when rated by MarketBeat users. However, 76.28% of users gave Alnylam Pharmaceuticals an outperform vote while only 72.33% of users gave Incyte an outperform vote. CompanyUnderperformOutperformAlnylam PharmaceuticalsOutperform Votes115876.28% Underperform Votes36023.72% IncyteOutperform Votes122672.33% Underperform Votes46927.67% Do analysts recommend ALNY or INCY? Alnylam Pharmaceuticals currently has a consensus target price of $312.30, suggesting a potential upside of 15.23%. Incyte has a consensus target price of $74.88, suggesting a potential upside of 23.39%. Given Incyte's higher probable upside, analysts plainly believe Incyte is more favorable than Alnylam Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Alnylam Pharmaceuticals 1 Sell rating(s) 4 Hold rating(s) 20 Buy rating(s) 0 Strong Buy rating(s) 2.76Incyte 1 Sell rating(s) 13 Hold rating(s) 5 Buy rating(s) 0 Strong Buy rating(s) 2.21 Do institutionals & insiders have more ownership in ALNY or INCY? 93.0% of Alnylam Pharmaceuticals shares are owned by institutional investors. Comparatively, 97.0% of Incyte shares are owned by institutional investors. 1.5% of Alnylam Pharmaceuticals shares are owned by company insiders. Comparatively, 17.6% of Incyte shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth. Which has better valuation & earnings, ALNY or INCY? Incyte has higher revenue and earnings than Alnylam Pharmaceuticals. Alnylam Pharmaceuticals is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAlnylam Pharmaceuticals$2.25B15.61-$278.16M-$2.17-124.89Incyte$4.24B2.77$32.62M$0.27224.74 SummaryIncyte beats Alnylam Pharmaceuticals on 13 of the 18 factors compared between the two stocks. Remove Ads Get Incyte News Delivered to You Automatically Sign up to receive the latest news and ratings for INCY and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INCY vs. The Competition Export to ExcelMetricIncyteCommercial physical research IndustryMedical SectorNASDAQ ExchangeMarket Cap$11.74B$3.68B$5.64B$8.06BDividend YieldN/A2.02%4.57%4.01%P/E Ratio224.75113.4223.1319.03Price / Sales2.77153.19383.8993.17Price / Cash128.9434.5738.1634.64Price / Book3.412.606.944.33Net Income$32.62M$118.81M$3.20B$247.06M7 Day Performance-2.00%-3.31%-2.33%-0.37%1 Month Performance-17.44%-19.43%2.84%-3.85%1 Year Performance6.51%-11.63%10.75%1.27% Incyte Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INCYIncyte4.7096 of 5 stars$60.68-0.9%$74.88+23.4%+6.2%$11.74B$4.24B224.752,320Positive NewsALNYAlnylam Pharmaceuticals4.2649 of 5 stars$290.70+2.6%$312.30+7.4%+75.5%$37.63B$2.25B-133.962,230High Trading VolumeBIIBBiogen4.9116 of 5 stars$141.60+0.5%$213.33+50.7%-35.1%$20.73B$9.68B12.658,720Positive NewsUTHRUnited Therapeutics4.9404 of 5 stars$319.86+2.2%$388.25+21.4%+26.6%$14.37B$2.88B14.05980Insider TradeShort Interest ↓Positive NewsBMRNBioMarin Pharmaceutical4.9038 of 5 stars$71.99+1.1%$94.00+30.6%-17.8%$13.73B$2.85B32.723,401Options VolumeNBIXNeurocrine Biosciences4.9292 of 5 stars$115.60+3.3%$165.24+42.9%-17.3%$11.53B$2.36B35.141,200Analyst ForecastNews CoveragePositive NewsEXELExelixis4.5566 of 5 stars$37.72+2.1%$37.59-0.3%+54.4%$10.56B$2.17B21.311,220Upcoming EarningsAnalyst ForecastNews CoveragePositive NewsEXASExact Sciences4.5798 of 5 stars$47.09+3.2%$70.83+50.4%-32.7%$8.75B$2.76B-8.456,400News CoveragePositive NewsRGENRepligen4.7538 of 5 stars$145.15+3.7%$178.64+23.1%-25.8%$8.15B$634.44M-284.612,020Positive NewsHALOHalozyme Therapeutics4.283 of 5 stars$64.02-1.7%$62.78-1.9%+58.3%$7.91B$1.02B18.66390Positive NewsMDGLMadrigal Pharmaceuticals3.5502 of 5 stars$346.40+1.4%$378.44+9.3%+30.3%$7.65B$180.13M-13.8190Positive News Remove Ads Related Companies and Tools Related Companies Alnylam Pharmaceuticals Competitors Biogen Competitors United Therapeutics Competitors BioMarin Pharmaceutical Competitors Neurocrine Biosciences Competitors Exelixis Competitors Exact Sciences Competitors Repligen Competitors Halozyme Therapeutics Competitors Madrigal Pharmaceuticals Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INCY) was last updated on 3/28/2025 by MarketBeat.com Staff From Our PartnersElon Warns: Exec Order 14024 Targets DollarExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredEx CIA predicts 40% “double crash” – April 11The scientists here don’t study deadly viruses… directed energy weapons… or even weather control technology… ...Paradigm Press | SponsoredA $6.9 Trillion Cash Tsunami Is Coming – Move Your Money NOWExpert: "Prepare For the Mother of All Melt-Ups" In the wake of Wall Street volatility, stock-picking legen...Stansberry Research | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredWarning: “DOGE Collapse” imminentElon Strikes Back You may already sense that the tide is turning against Elon Musk and DOGE. Just this week...Altimetry | SponsoredYour Wealth is Under AttackPlease don't wait—this is your moment to take action. Download your Wealth Protection Guide now, claim your fr...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Incyte Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Incyte With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy INCY Stock Free INCY Stock Alerts